• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Heat-stable drug formulation offers new option to prevent postpartum bleeding

June 28, 2018 By Sarah Faulkner

Ferring PharmaceuticalsData from a collaboration between Ferring Pharmaceuticals, Merck (NYSE:MRK) and the World Health Organization showed that a heat-stable formulation of carbetocin is as effective as oxytocin for the prevention of excessive bleeding following vaginal birth.

Millions of women are affected by postpartum hemorrhage every year, according to Ferring Pharmaceuticals. Traditionally, women are given oxytocin to prevent the deadly condition. But oxytocin has to be stored and transported at 2 – 8°C, which is not always possible in countries where adequate storage and distribution resources are scarce.

To address this problem, scientists at Ferring Pharmaceuticals developed a heat-stable formulation of carbetocin that can maintain its efficacy for at least three years at 30°C or six months at 40°C.

The Champion trial, which set out to compare the heat-stable formulation of carbetocin against oxytocin, included nearly 30,000 women in ten countries, according to Ferring Pharmaceuticals. The WHO, Ferring Pharmaceuticals and MSD for Mothers published the results of the trial in the New England Journal of Medicine.

Results showed that carbetocin is clinically non-inferior to oxytocin for the primary outcome of greater than 500 mL of blood loss or use of additional uterotonic, the pharma company touted.

“This is an important step forwards in PPH prevention and these results pave the way for heat-stable carbetocin to potentially save the lives of thousands of women, especially in areas where cold-chain transport and storage is not feasible,” Klaus Dugi, CMO at Ferring Pharmaceuticals, said in prepared remarks.”We will now work with the WHO and MSD for Mothers to make heat-stable carbetocin available in countries where it is needed most, protecting women and families around the world.”

“No woman should die giving life, and our mission is to give mothers around the world access to affordable, life-saving medical interventions,” Julie Gerberding, Merck’s chief patient officer, said in a press release. “Prevention is key, which is why we are collaborating on the Champion project. The collaboration has brought innovation developed in the private sector into the public sector in an effort to address unmet needs in countries where the majority of maternal deaths occur.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: ferringpharmaceuticals, Merck, World Health Organization

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS